Sandu Pharmaceuticals Ltd — Updates, 04-06-2025: Company Update

Sandu Pharmaceuticals has responded to a show cause notice from the Maharashtra GST Department regarding excess input tax credit of Rs. 96.48 lakh, including interest and penalty, related to discrepancies in GST filings. The company clarified that the delay in informing the exchange about the notice was unintentional and due to outdated email contacts with the GST authorities. Management expects a favorable outcome based on internal assessment and legal advice and does not anticipate any impact on the company’s financials or operations. Steps have been taken to update the authorized contact details to avoid future communication delays.